Increasing trends in the use of the Precivia? intravitreal injection assist device across the UK

Background Intravitreal anti-VEGF injections are the most frequently performed outpatient procedure in the UK, the need for which continues to rise. To meet this demand, injection assist devices such as Precivia (R) are increasingly adopted to aid in their prompt and safe delivery. We present data on the usage of Precivia (R) intravitreal injection assist device across two district general hospitals and its distribution across the UK over five years.Methods A retrospective review was undertaken of all Precivia (R) assisted intravitreal injections delivered at Great Western Hospitals NHS Trust (GWH), and Gloucestershire and Cheltenham Hospitals NHS Trust (GCH) between 2015-2020. Data were also obtained from the Precivia (R) device UK distributor; Veni Vidi Medical.Results In GCH, 47,968 intravitreal injections were administered with Precivia (R): 5947 in year 1; 7058 in year 2; 9893 in year 3; 11,503 in year 4 and 13,567 injections in year 5, observing a 128.13% increase in the use of Precivia (R) over the five-year-period. In GWH, 26,923 injections were administered with Precivia (R): 4232 in year 1; 5117 in year 2; 5437 in year 3; 5878 in year 4 and 6259 in year 5, observing a 47.89% increase in Precivia (R) injections over a five-year study period. The number of Precivia (R) devices distributed across the UK similarly increased including 42,150 devices sold in 2015; 68,125 in 2016; 72,575 in 2017; 88,325 in 2018; 112,850 in 2019 and 115,125 in 2020 observing a 173.31% increase in five years.Conclusion An increasing trend in the use of the Precivia (R) intravitreal injection assist device was observed across the UK.